Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | PBK | Q96KB5 | 6/20 | 0.44 |
| ▸ | GHSR | Q92847 | 3/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618497 | 1.00 | SYK (0.51) | SYKCHEK1SMYD3MAPK1OPRK1 | |
| SCHEMBL3610636 | 1.00 | SYK (0.51) | SYKCHEK1SMYD3MAPK1OPRK1 | |
| SCHEMBL3611294 | 0.93 | SMYD3 (0.47) | SYKCHEK1SMYD3PBKGHSR | |
| SCHEMBL3616197 | 0.93 | SMYD3 (0.47) | SYKCHEK1SMYD3PBKGHSR | |
| SCHEMBL3611297 | 0.93 | SMYD3 (0.47) | SYKCHEK1SMYD3PBKGHSR | |
| SCHEMBL25532114 | 0.83 | MAPK1 (0.47) | SYKCHEK1SMYD3MAPK1OPRK1 | |
| SCHEMBL3610802 | 0.82 | SMYD3 (0.67) | SYKCHEK1SMYD3MAPK1OPRK1 | |
| SCHEMBL3610798 | 0.82 | SMYD3 (0.67) | SYKCHEK1SMYD3MAPK1OPRK1 | |
| SCHEMBL4558593 | 0.81 | HRH4 (0.51) | SYKCHEK1SMYD3MAPK1OPRK1 | |
| SCHEMBL3611824 | 0.80 | SMYD3 (0.47) | SYKSMYD3PBKNSD2SETD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SYK 3494/4885CHEK1 1121/4885SMYD3 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.